NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update

NeuroSense published its financial results for the quarter ended June 30, 2023 and provided a business update.

Business Updates include –

  • Capital Raise of $4.5 Million
  • Phase 2b Amyotrophic Lateral Sclerosis (ALS) PARADIGM Trial Completed Patient Enrollment
  • Strategic Scientific Agreement with Biogen
  • Phase 2 Alzheimer’s Disease (AD) Trial Under Preparation

and more..

Share:

Join Our Newsletter

Neurosense
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.